BACKGROUND: Although many believe that platelet glycoprotein IIb/IIIa inhibitors should be used only in acute coronary syndrome patients undergoing percutaneous coronary intervention, supporting data from randomized clinical trials are tenuous. The assumption that these agents are useful only in conjunction with percutaneous coronary intervention is based primarily on inappropriate subgroup analyses performed across the glycoprotein IIb/IIIa inhibitor trials. METHODS AND RESULTS: We describe the problems with these analytical techniques and demonstrate that different approaches to the question can result in opposing answers. CONCLUSIONS: Clinical-practice decisions and practice guidelines should be based on overall trial results and not analyses of post-randomization subgroups.
BACKGROUND: Although many believe that platelet glycoprotein IIb/IIIa inhibitors should be used only in acute coronary syndromepatients undergoing percutaneous coronary intervention, supporting data from randomized clinical trials are tenuous. The assumption that these agents are useful only in conjunction with percutaneous coronary intervention is based primarily on inappropriate subgroup analyses performed across the glycoprotein IIb/IIIa inhibitor trials. METHODS AND RESULTS: We describe the problems with these analytical techniques and demonstrate that different approaches to the question can result in opposing answers. CONCLUSIONS: Clinical-practice decisions and practice guidelines should be based on overall trial results and not analyses of post-randomization subgroups.
Authors: David H Fitchett; Bjug Borgundvaag; Warren Cantor; Eric Cohen; Sanjay Dhingra; Stephen Fremes; Milan Gupta; Michael Heffernan; Heather Kertland; Mansoor Husain; Anatoly Langer; Eric Letovsky; Shaun G Goodman Journal: Can J Cardiol Date: 2006-06 Impact factor: 5.223
Authors: Renato D Lopes; David Garcia; Richard C Becker; Christopher B Granger; L Kristin Newby; John H Alexander; E Marc Jolicoeur; Allison Handler; Karen S Pieper; Antonio C Carvalho; Helio P Guimaraes; Dalton A F Chamone; Antonio C Baruzzi; Fabio S Machado; Ari Timerman; Antonio C Lopes Journal: J Thromb Thrombolysis Date: 2010-05 Impact factor: 2.300
Authors: Paul W Armstrong; Wei-Ching Chang; Lars Wallentin; Patrick Goldstein; Christopher B Granger; Kris Bogaerts; Thierry Danays; Frans Van de Werf Journal: CMAJ Date: 2006-05-09 Impact factor: 8.262
Authors: Renato D Lopes; Richard C Becker; John H Alexander; Paul W Armstrong; Robert M Califf; Mark Y Chan; Mark Crowther; Christopher B Granger; Robert A Harrington; Elaine M Hylek; Stefan K James; E Marc Jolicoeur; Kenneth W Mahaffey; L Kristin Newby; Eric D Peterson; Karen S Pieper; Frans Van de Werf; Lars Wallentin; Harvey D White; Antonio C Carvalho; Roberto R Giraldez; Helio P Guimaraes; Helena B Nader; Renato A K Kalil; Joyce M A Bizzachi; Antonio C Lopes; David A Garcia Journal: J Thromb Thrombolysis Date: 2011-08 Impact factor: 2.300
Authors: Saman Rasoul; Jan Paul Ottervanger; Menko Jan de Boer; Jan Henk E Dambrink; Harry Suryapranata; Jan C A Hoorntje; A T Marcel Gosselink; Arnoud W J van 't Hof Journal: J Thromb Thrombolysis Date: 2007-03-02 Impact factor: 2.300